Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott has announced a 4.4% increase in its quarterly common dividend, raising it to 47 cents per share, marking the 50th consecutive year of dividend growth. This payment will be made on Feb. 15, 2022, to shareholders on record by Jan. 14, 2022. The company also authorized a new $5 billion share repurchase program, supporting its strategy for sustainable shareholder returns and innovation. Abbott boasts a history of 392 consecutive quarterly dividends and is a member of the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE: ABT) has launched Similac 360 Total Care, the first U.S. infant formula featuring a unique blend of five human milk oligosaccharides (HMOs) to support overall baby health, immune system, and brain development. This formula addresses the needs of the nearly 75% of parents using infant formula within the first six months due to various reasons. With over 20 years of research on HMOs, Abbott aims to narrow the gap between breast milk and formula, offering parents a scientifically backed alternative to nourish their babies.
Summary not available.
Abbott (NYSE: ABT) announced positive data from the Leadless II study for its investigational Aveir leadless pacemaker, which showed an impressive 98% successful implantation rate among 200 patients. The device met primary safety and efficacy endpoints, with 96% of patients experiencing no serious adverse effects and 95.9% achieving effective pacing at six weeks post-implant. The findings were presented at the Asia Pacific Heart Rhythm Society's annual session and submitted for FDA review, signaling potential advancements in minimally invasive cardiac care.
Abbott and the American Diabetes Association have launched a community health partnership in Columbus, Ohio, targeting healthcare disparities for people of color living with diabetes. The initiative will educate and provide up to 150 Black adults with access to Abbott's FreeStyle Libre glucose monitoring technology. Black Americans face a 60% higher diabetes diagnosis rate and significant barriers to managing the disease effectively. This program aims to improve health outcomes and access to diabetes care technology.
Abbott reported strong financial results for Q3 2021, with sales reaching $10.9 billion, a 23.4% increase year-over-year. GAAP diluted EPS was $1.17, while adjusted diluted EPS grew 42.9% to $1.40. The company projects full-year diluted EPS of $3.55 to $3.65 and adjusted EPS of $5.00 to $5.10, indicating potential 38.4% growth. Significant product launches and acquisitions contributed to this growth, including FDA approvals for new medical devices and an acquisition of Walk Vascular.
On October 18, 2021, Abbott (NYSE: ABT) announced a partnership with Real Madrid to enhance children's health and nutrition worldwide. The initiative will provide nutritional science for the football club's teams and support programs run by the Real Madrid Foundation. Jason Sudeikis, the star of Ted Lasso, participated in an event at the New York Stock Exchange, promoting the partnership alongside teens from the Foundation's Social Sports School. The collaboration aims to impact thousands of children's health and support their potential.
Abbott (NYSE: ABT) has partnered with Real Madrid as its Health Sciences and Nutrition Partner for three years. This collaboration will support education, sports, and social welfare activities for at-risk children in 80 countries, alongside providing nutritional assistance to the men's and women's teams. Abbott aims to tackle malnutrition through this initiative, working with the Real Madrid Foundation to enhance children's health and well-being globally. This partnership aligns with Abbott's goal to improve the lives of over 3 billion people by 2030.
Abbott has established the Abbott Center for Malnutrition Solutions to tackle global malnutrition, focusing on vulnerable groups including mothers, infants, and aging adults. This initiative aligns with Abbott's 2030 Sustainability Plan, aiming to enhance nutrition access for over 3 billion people. Key strategies include expert collaboration, tailored solutions, leveraging scientific innovation, and sustainable practices. Malnutrition is a widespread issue, affecting 1 in 3 people globally, and Abbott plans to use its expertise to make a significant impact.
Abbott (NYSE: ABT) will release its third-quarter 2021 financial results on Wednesday, Oct. 20, 2021, before market opening. Following this, a live webcast of the earnings conference call will occur at 8 a.m. Central time. Interested parties can access it through Abbott's Investor Relations website. Abbott is a global healthcare leader, operating in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with a team of 109,000 colleagues.